Drug Trial Radar · NCT06334432
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
466
Planned (sponsor's estimate)
Start
Mar 14, 2024
Primary completion
Mar 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Nuvation Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- HER2-negative Breast Cancer
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Pancreatic Cancer
- Platinum-resistant Ovarian Cancer (PROC)
Interventions
NUV-1511Drug
Novel small molecule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumorsTime frame: First 28 days of dosing (DLT evaluation period)
- Phase 1: Identify recommended dosing schedule(s) and corresponding Phase 2 dose(s) (RP2D(s))Time frame: First 28 days of dosing (DLT evaluation period)
- Phase 2: Evaluate the efficacy of NUV-1511 in advanced solid tumors and selected tumor type(s)Time frame: From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
- Phase 2: Confirm the optimal NUV-1511 dose level/schedule for further developmentTime frame: Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
- Phase 2: Confirm the optimal NUV-1511 target tumor types for further developmentTime frame: Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Karmanos Cancer Center
Detroit, Michigan
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center
New York, New York
Carolina BioOncology Institute
Huntersville, North Carolina
NEXT Oncology
Irving, Texas
START Mountain
Salt Lake City, Utah
NEXT Oncology
Fairfax, Virginia
Fred Hutchinson
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.